Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
Measuring Acute Drug Demand in Humans
- Conditions
- Opioid Use DisorderOpioid Dependence
- Interventions
- Drug: Drug A (Blinded Drug)Drug: Drug B (Blinded Drug)Drug: Drug C (Blinded Drug)Drug: Drug D (Blinded Drug)Drug: Placebo
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 75
- Registration Number
- NCT05829655
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Efficacy of Suvorexant on Post-operative Sleep Disturbance
- Conditions
- Postoperative InsomniaPostoperative Delirium
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 92
- Registration Number
- NCT05823844
- Locations
- 🇺🇸
NewYork-Presbyterian Allen Hospital/CUMC Milstein Hospital Building, New York, New York, United States
REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 130
- Registration Number
- NCT05733286
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 71
- Registration Number
- NCT05656534
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
Orexin s Role in the Neurobiology of Substance Use Disorder
- Conditions
- Nicotine Dependence
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 140
- Registration Number
- NCT05630781
- Locations
- 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05593653
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Trial of Suvorexant for Sleep in Children With Autism
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 26
- Registration Number
- NCT05546554
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Suvorexant for Opioid/Stimulant Co-use
- Conditions
- Opioid Use DisorderStimulant Use Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT05546515
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
- Conditions
- PlaceboSuvorexantOpioid Use Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 120
- Registration Number
- NCT05145764
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- Conditions
- Healthy Non-dependent, Recreational Sedative UsersAbuse Potential
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT05106153
- Locations
- 🇺🇸
Altasciences Inc., Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.